These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 11726950)

  • 21. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 22. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 23. Enfuvirtide (Fuzeon) for HIV Infection.
    Med Lett Drugs Ther; 2003 Jun; 45(1159):49-50. PubMed ID: 12817195
    [No Abstract]   [Full Text] [Related]  

  • 24. Therapies. Raising the limits.
    Cohen J
    Science; 2002 Jun; 296(5577):2322. PubMed ID: 12089423
    [No Abstract]   [Full Text] [Related]  

  • 25. New-Fill on "hold" and open-label for T-20.
    Berger DS
    Posit Aware; 2002; 13(1):64-5. PubMed ID: 12216532
    [No Abstract]   [Full Text] [Related]  

  • 26. Enfuvirtide.
    LaBonte J; Lebbos J; Kirkpatrick P
    Nat Rev Drug Discov; 2003 May; 2(5):345-6. PubMed ID: 12755128
    [No Abstract]   [Full Text] [Related]  

  • 27. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 28. [New drug class blocks virus-cell fusion. HIV not admitted].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 30. Fusion inhibitor approved.
    AIDS Patient Care STDS; 2003 May; 17(5):253. PubMed ID: 12816619
    [No Abstract]   [Full Text] [Related]  

  • 31. Fuzeon data review.
    GMHC Treat Issues; 2003 Mar; 17(3):6. PubMed ID: 12728857
    [No Abstract]   [Full Text] [Related]  

  • 32. New package inserts for efavirenz and T-20.
    AIDS Clin Care; 2007 Mar; 19(3):24. PubMed ID: 17595717
    [No Abstract]   [Full Text] [Related]  

  • 33. [FDA approved the first of a new class of antiretrovirals for adults and children with advanced HIV infection].
    Rev Panam Salud Publica; 2003 Jul; 14(1):57-8. PubMed ID: 12952609
    [No Abstract]   [Full Text] [Related]  

  • 34. Long path to approval. A look back at the road to Fuzeon.
    GMHC Treat Issues; 2003 Mar; 17(3):1-5. PubMed ID: 12728856
    [No Abstract]   [Full Text] [Related]  

  • 35. 9th National Retrovirus Conference: new treatments, new choices.
    Laurence J
    AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical perspective of fusion inhibitors for treatment of HIV.
    Rockstroh JK; Mauss S
    J Antimicrob Chemother; 2004 May; 53(5):700-2. PubMed ID: 15044424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV fusion and its inhibition in antiretroviral therapy.
    Greenberg M; Cammack N; Salgo M; Smiley L
    Rev Med Virol; 2004; 14(5):321-37. PubMed ID: 15334539
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 39. FUZEON (enfuvirtide, T-20). Breaking barriers or breaking the bank?
    Sharp M; Camp R
    GMHC Treat Issues; 2003 Mar; 17(3):7-8. PubMed ID: 12728858
    [No Abstract]   [Full Text] [Related]  

  • 40. Blocking HIV entry.
    Buzko OV; Shokat KM
    Nat Struct Biol; 1999 Oct; 6(10):906-8. PubMed ID: 10504719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.